Forest Laboratories Inc (FRX) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
909 THIRD AVENUE NEW YORK, NY 10022 |
| State of Incorp. | DE |
| Fiscal Year End | March 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in millions)
| 3/31/2014 | 3/31/2013 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 1,675 | |||
| Cash and cash equivalents | 936 | |||
| Short-term investments | 739 | |||
| Receivables | (2) | |||
| Inventory, net of allowances, customer advances and progress billings | 394 | |||
| Inventory | 394 | |||
| Prepaid expense | ✕ | |||
| Other current assets | 135 | |||
| Other undisclosed current assets | 746 | |||
| Total current assets: | 2,948 | |||
| Noncurrent Assets | ||||
| Property, plant and equipment | 377 | |||
| Long-term investments and receivables | 1,349 | |||
| Long-term investments | 1,349 | |||
| Intangible assets, net (including goodwill) | 2,841 | |||
| Goodwill | 713 | |||
| Intangible assets, net (excluding goodwill) | 2,128 | |||
| Other noncurrent assets | 115 | |||
| Total noncurrent assets: | 4,682 | |||
| TOTAL ASSETS: | 7,630 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 1,180 | |||
| Employee-related liabilities | 182 | |||
| Accounts payable | 157 | |||
| Accrued liabilities | 840 | |||
| Other undisclosed current liabilities | (182) | |||
| Total current liabilities: | 998 | |||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 851 | |||
| Deferred tax liabilities, net | 283 | |||
| Liability for uncertainty in income taxes | 567 | |||
| Other liabilities | ||||
| Other undisclosed noncurrent liabilities | 36 | |||
| Total noncurrent liabilities: | 887 | |||
| Total liabilities: | 1,884 | |||
| Equity | ||||
| Equity, attributable to parent | 5,745 | |||
| Common stock | 43 | |||
| Treasury stock, value | (5,162) | |||
| Additional paid in capital | 1,799 | |||
| Accumulated other comprehensive income | 10 | |||
| Retained earnings | 9,055 | |||
| Total equity: | 5,745 | |||
| TOTAL LIABILITIES AND EQUITY: | 7,630 | |||
Income Statement (P&L) ($ in millions)
| 3/31/2014 | 3/31/2013 | ||
|---|---|---|---|
| Revenues | 3,126 | ||
| Revenue, net | 3,094 | ||
| Cost of revenue (Cost of Goods and Services Sold) | (649) | ||
| Gross profit: | 2,477 | ||
| Operating expenses | (2,622) | ||
| Operating income (loss): | (145) | ||
| Nonoperating income (expense) | 32 | ||
| Investment income, nonoperating | 29 | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 68 | ||
| Income (loss) from continuing operations before income taxes: | (45) | ||
| Income tax benefit | 13 | ||
| Income (loss) from continuing operations: | (32) | ||
| Income (loss) before gain (loss) on sale of properties: | (32) | ||
| Net income (loss) available to common stockholders, diluted: | (32) | ||
Comprehensive Income ($ in millions)
| 3/31/2014 | 3/31/2013 | ||
|---|---|---|---|
| Net income (loss): | (32) | ||
| Other comprehensive income | 13 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (19) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.